Upstate Active Clinical Trials

Study Title:

Celgene Protocol CC-5013-CLL-002: A Phase 3, Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study of the Efficacy and Safety of Lenalidomide (Revlimid) as Maintenance Therapy for Patients with B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The CONTINUUM Trial)

Upstate Institutional Review Board (IRB) Number:

230326

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Bernard J Poiesz, MD

ClinicalTrials.Gov ID:

NCT00774345

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Patricia M Benz
Phone: 315-464-8253
Email: benzp@upstate.edu

Return to Previous Page || Search Again